Home
NewsNewsINVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
INVO Fertility, Inc., a healthcare services fertility company that helps people get advanced reproductive treatment by setting up, acquiring as well as running fertility clinics along with related businesses and technologies, on March 5, 2026, went ahead and announced that its Wisconsin clinic would start using time-lapse incubation technology. This integration shows that INVO is indeed dedicated to providing modern, high-quality lab care and creative patient solutions, as well as to improving the quality of labs and clinics across its growing network.
According to COO of INVO, April McGhee, “INVO Fertility is proud to introduce this time-lapse incubation technology as part of our ongoing focus on quality and innovation and the expansion of additional patient service offerings. This technology enhances the tools available to our embryology teams while aligning with our commitment to delivering thoughtful, patient-centred fertility care.”
INVO is looking out to improve its clinics and help its clinical and laboratory teams and also throttle its mission of providing accessible, patient-centred fertility care by using proven new ideas like time-lapse incubation. This adoption shows that the company is keeping its promise to invest in cutting-edge technologies that improve the treatment journey for patients. It is also part of the company's larger plan to responsibly integrate cutting-edge reproductive technologies that provide real value to patients and doctors.
Remarks CEO Steve Shum, “Our approach to innovation is intentional. We focus on technologies that may enhance quality and outcomes while staying true to our mission of expanding access to fertility care through continuous, responsible innovation.”
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
